New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
16:50 EDTMNKDMannKind says it is in talks with partners for Afrezza
MannKind says it is in talks with partners for Afrezza and the company sees needing 6 to 8 weeks post the drug's PDUFA date to finalize any partnerships, which it expects to be royalty based or profit sharing arrangments. MannKind sees pricing Affrezza comparable to injected insulin. MannKind notes that the PDUFA date for Afrezza is July 15. Comments made earlier by CFO Matthew Pfeffer at the Goldman Sachs Global Healthcare conference.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
09:18 EDTMNKDOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Glu Mobile (GLUU), up 21.9%... Solaredge Technologies (SEDG), up 11.2%... Cadence Design (CDNS), up 6.6%. ALSO HIGHER: VirnetX Holding (VHC), up 91.7% after the company won a $625.6M verdict in favor of in a patent infringement lawsuit against Apple (AAPL)... Viacom (VIAB), up 5.1% after CNBC's David Faber reported that sources said CEO Philippe Dauman is likely to be named Chairman despite objections from Shari Redstone. DOWN AFTER EARNINGS: GoPro (GPRO), down 16.4%... ConocoPhillips (COP), down 2.9%... Dunkin Brands (DNKN), down 2.1%... Philip Morris (PM), down 3.2%. ALSO LOWER: L Brands (LB), down 3.3% after providing Q4 guidance, reporting January Same-Store Sales were down 2%... MannKind (MNKD), down 8.1% after Piper Jaffray analyst Joshua Schimmer calls the company a penny stock with a mid-cap valuation.
06:05 EDTMNKDPiper calls MannKind a penny stock with a mid-cap valuation
Piper Jaffray analyst Joshua Schimmer calls MannKind's business strategy "flawed and desperate" following the company's conference call yesterday to discuss recent developments. The company is trying to appeal to "less sophisticated retail investors," Schimmer tells investors in a research note. MannKind does not have the ability to generate adequate revenue to offset the spending requirements over the next 12 months for Afrezza, the analyst contends. Schimmer sees no reason to own the shares and believes the likelihood that the company declares bankruptcy this year "is not out of the realm of possibility." He calls MannKind a "penny stock company with a mid-cap valuation." The analyst reiterates an Underweight rating on the biopharmaceutical company with a 5c price target. The stock closed yesterday down 1c to 99c.
January 28, 2016
05:43 EDTMNKDStocks with implied volatility movement; BTU MNKD
Subscribe for More Information
January 27, 2016
09:46 EDTMNKDMannKind to host business news update conference call
Subscribe for More Information
January 26, 2016
15:31 EDTMNKDMannKind exploring potential sale, Reuters reports
MannKind (MNKD), whose shares have plunged 40% since Sanofi (SNY) terminated an agreement for the development and commercialization of inhaled insulin drug Afrezza, is now exploring its strategic options, including a potential sale, reported Reuters, citing people familiar with the matter. MannKind shares are up about 20% to 90c in afternoon trading following the report. Reference Link
14:33 EDTMNKDMannKind exploring alternatives, including potential sale, Reuters reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use